Open-label study to assess reduction of background asthma medication while sustaining asthma control and clinical remission with tezepelumab in patients 12-80yrs with severe asthma. - ARRIVAL

Study identifier:D5180C00047

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for Tezepelumab-treated Patients with Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission

Medical condition

Severe Asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol

Sex

All

Estimated Enrollment

300

Study type

Interventional

Age

12 Years - 80 Years

Date

Study Start Date: 30 Sept 2024
Estimated Primary Completion Date: 30 Jun 2027
Estimated Study Completion Date: 30 Jun 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Fortrea

Inclusion and exclusion criteria